market-trends is the sole category represented across all 1 tracked stories. Lightwave Logic, Inc. is most often covered alongside BioLargo, Inc., which appears in 1 of these 1 story. They are better corroborated than the beat average, carrying 5 original sources each against 4.1 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Lightwave Logic, Inc.
market-trends is the sole category represented across all 1 tracked stories. Lightwave Logic, Inc. is most often covered alongside BioLargo, Inc., which appears in 1 of these 1 story. They are better corroborated than the beat average, carrying 5 original sources each against 4.1 for the same window. At 5, the average consequence score sits below the same-window beat average of 6. Lightwave Logic, Inc. appears in 1 tracked Healthcare story from March 9, 2026.
Stories tracked
1
Sources per story
5
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 30 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Lightwave Logic, Inc.. Shared-story counts are live from our verified record — not editorial picks.
REGENXBIO and BioLargo reported Q4 2025 results marked by wider-than-expected losses, reflecting a challenging environment for high-growth biotech and environmental health firms. As REGENXBIO navigates the costly gene therapy pipeline, the broader market trend shows a tightening of fiscal performance across specialized technology sectors.